J&J tries to back out of nanopar­ti­cle li­cense agree­ment — but Alk­er­mes says 'not so fast'

Putting a damper on a years-long kin­ship, J&J says it’s part­ly back­ing out of two li­cense agree­ments for Alk­er­mes’ nanopar­ti­cle tech­nol­o­gy, which the phar­ma gi­ant claims it doesn’t use.

There’s on­ly one prob­lem: Alk­er­mes doesn’t agree, and CEO Richard Pops says he’ll “ex­plore all op­tions” at the com­pa­ny’s dis­pos­al to pre­vent J&J from in­fring­ing on what he says are Alk­er­mes’ con­trac­tu­al rights.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER